Topics

KOL Perspectives: Perceptions of recent upcoming data for key HBV pipeline agents [Report Updated: 02102018] Prices from USD $2125

04:41 EST 29 Nov 2018 | BioPortfolio Report Blog

KOL Perspectives: Perceptions of recent upcoming data for key HBV pipeline agents


Summary


This KOL Insight briefing focuses on KOLs views of recent upcoming data for key HBV pipeline agents.


Questions topics

Further Phase I data required for Roche's capsid inhibitor RO7049389

Replicor's US trial plans and transition from IV to subcutaneous REP 2139

Efficacy of Spring Bank's inarigivir at 100mg in the Phase II ACHIEVE trial

Expected role for inarigivir in HBV

Efficacy of Arbutus's Q2W IV ARB1467

ARB1467, TDF + PegIFN trial design, potential for functional cure, regimen acceptability

Future development of Arbutus's nextgeneration RNAi therapeutic AB729For internal use only


Key Highlights


Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ6379 ABIH0731, with most concluding that Phase I data is insufficien

KOLs agree Replicor is making positive steps towards REP 2139's development, but similar efficacy safety must be demonstrated in the US trials and for the SC formulation

Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our HBV key opinion leaders KOLs.


In total, we conducted interviews with 10 KOLs

5 Europebased 5 N. Americabased

Interviews performed during Sept 2018


KOL data is analyzed to produce

Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on "recent upcoming data for key HBV pipeline agents"

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of HBV

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: Perceptions of recent upcoming data for key HBV pipeline agents [Report Updated: 02102018] Prices from USD $2125

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: Perceptions of recent upcoming data for key HBV pipeline agents [Report Updated: 02102018] Prices from USD $2125"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...